Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 May;93(5):402-8.
doi: 10.1038/clpt.2013.2. Epub 2013 Jan 16.

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants

Affiliations
Free PMC article
Review

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants

J K Hicks et al. Clin Pharmacol Ther. .
Free PMC article

Abstract

Polymorphisms in CYP2D6 and CYP2C19 affect the efficacy and safety of tricyclics, with some drugs being affected by CYP2D6 only, and others by both polymorphic enzymes. Amitriptyline, clomipramine, doxepin, imipramine, and trimipramine are demethylated by CYP2C19 to pharmacologically active metabolites. These drugs and their metabolites, along with desipramine and nortriptyline, undergo hydroxylation by CYP2D6 to less active metabolites. Evidence from published literature is presented for CYP2D6 and CYP2C19 genotype-directed dosing of tricyclic antidepressants.

Figures

Figure 1
Figure 1
Major metabolic pathway of amitriptyline and nortriptyline.

Comment in

Similar articles

See all similar articles

Cited by 119 articles

See all "Cited by" articles

Publication types

MeSH terms

Substances

Feedback